Anosognosia in Alzheimer's Pathology: Validation of a New Measure.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS
Christian Terry, Len Lecci
{"title":"Anosognosia in Alzheimer's Pathology: Validation of a New Measure.","authors":"Christian Terry, Len Lecci","doi":"10.1093/arclin/acae020","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Two studies were performed to validate a brief measure of cognitive insight and compare it to an empirical model - the Cognitive Awareness Model (CAM).</p><p><strong>Method: </strong>A pilot study included 31 (52% male; Mage = 69.42) patients from an outpatient neuropsychological assessment clinic. Seven patients were diagnosed with likely Alzheimer's dementia (AD), 15 mild cognitive impairment (MCI), and 9 no diagnosis (i.e., cognitively normal; CN). The Cognitive Coding Form (CCF) and several other measures were administered. Study 2 entailed archival data extraction of 240 patients (80 CN, 80 MCI, and 80 AD; 53.3% female; Mage = 72.8) to examine whether the CCF predicts memory (Wechsler Memory Scale - IV) and executive functioning (Trail-Making Test B).</p><p><strong>Results: </strong>The pilot study found preliminary evidence of convergent and discriminant validity for the 8-item CCF. Study 2 confirmed that both patient-reported cognitive concerns (F(2,237) = 10.40, p < .001, ω2 = .07, power = .99) and, more strongly, CCF informant-patient discrepancy scores (F(2,237) = 24.52, p < .001, ω2 = .16, power = .99) can distinguish CNs from those with MCI and AD. A regression indicated that depression (5.5%; β = -.38, p < .001) and TMT-B (13%; β = -.43, p < .001), together accounted for 18.5% of the variance in insight (R2 = .19, F(2,219) = 26.10, p < .001), supporting the CAM.</p><p><strong>Conclusions: </strong>These studies establish an efficient measure of insight with high clinical utility and inform the literature on the role of insight in predicting performance in those with Alzheimer's pathology.</p>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"102","ListUrlMain":"https://doi.org/10.1093/arclin/acae020","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Two studies were performed to validate a brief measure of cognitive insight and compare it to an empirical model - the Cognitive Awareness Model (CAM).

Method: A pilot study included 31 (52% male; Mage = 69.42) patients from an outpatient neuropsychological assessment clinic. Seven patients were diagnosed with likely Alzheimer's dementia (AD), 15 mild cognitive impairment (MCI), and 9 no diagnosis (i.e., cognitively normal; CN). The Cognitive Coding Form (CCF) and several other measures were administered. Study 2 entailed archival data extraction of 240 patients (80 CN, 80 MCI, and 80 AD; 53.3% female; Mage = 72.8) to examine whether the CCF predicts memory (Wechsler Memory Scale - IV) and executive functioning (Trail-Making Test B).

Results: The pilot study found preliminary evidence of convergent and discriminant validity for the 8-item CCF. Study 2 confirmed that both patient-reported cognitive concerns (F(2,237) = 10.40, p < .001, ω2 = .07, power = .99) and, more strongly, CCF informant-patient discrepancy scores (F(2,237) = 24.52, p < .001, ω2 = .16, power = .99) can distinguish CNs from those with MCI and AD. A regression indicated that depression (5.5%; β = -.38, p < .001) and TMT-B (13%; β = -.43, p < .001), together accounted for 18.5% of the variance in insight (R2 = .19, F(2,219) = 26.10, p < .001), supporting the CAM.

Conclusions: These studies establish an efficient measure of insight with high clinical utility and inform the literature on the role of insight in predicting performance in those with Alzheimer's pathology.

阿尔茨海默氏症病理中的失认症:新测量方法的验证
目的我们进行了两项研究,以验证认知洞察力的简短测量方法,并将其与经验模型--认知认知模型(CAM)--进行比较:一项试点研究纳入了 31 名(52% 为男性;Mage = 69.42)来自神经心理评估门诊的患者。其中 7 名患者被诊断为阿尔茨海默氏症痴呆(AD),15 名患者被诊断为轻度认知障碍(MCI),9 名患者未被诊断(即认知正常;CN)。研究人员采用了认知编码表(CCF)和其他一些测量方法。研究2需要提取240名患者(80名CN患者、80名MCI患者和80名AD患者;53.3%为女性;年龄=72.8岁)的档案数据,以检验CCF是否能预测记忆(韦氏记忆量表-IV)和执行功能(追踪测试B):试验研究发现,8个项目的CCF具有初步的收敛性和区分性。研究2证实,患者报告的认知问题(F(2,237) = 10.40,p < .001,ω2 = .07,power = .99)以及更强的CCF信息提供者-患者差异得分(F(2,237) = 24.52,p < .001,ω2 = .16,power = .99)可以将CNs与MCI和AD患者区分开来。回归结果表明,抑郁(5.5%;β = -.38,p < .001)和TMT-B(13%;β = -.43,p < .001)共占洞察力变异的18.5%(R2 = .19,F(2,219) = 26.10,p < .001),支持CAM:这些研究建立了一种高效的洞察力测量方法,具有很高的临床实用性,并为有关洞察力在预测阿尔茨海默氏症患者表现方面的作用的文献提供了信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
ACS Applied Bio Materials
ACS Applied Bio Materials Chemistry-Chemistry (all)
CiteScore
9.40
自引率
2.10%
发文量
464
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信